Lilly to pay up to $660M in new deal with PRISM BioLab; Boehringer partners with Phenomic AI

Plus, news about Ascendis Pharma, Biolexis, Aperiam Bio, BiomX and Italfarmaco:

DEALS

Eli Lilly inks new deal with PRISM BioLab: The Indianapolis Big Pharma is making an undisclosed upfront payment and could eventually pay up to $660 million to the Japanese company for work on protein-protein interactions. The pact starts with one target, and Lilly could add two more. The companies kept all other details under wraps. PRISM already works with companies like Eisai, Boehringer Ingelheim, Merck KGaA and Roche. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Parkinson’s Dementia May Be Less Common Than Once Thought

Parkinson’s disease dementia may occur less frequently than previously thought. The estimated risk of dementia increased with disease duration. Age, male sex, and lower educational

August 8, 2024

‘Eye Opening’: Chatbot Outperforms Ophthalmologists

An artificial intelligence (AI) chatbot largely outperformed a panel of specialist ophthalmologists when given prompts about glaucoma and retinal health, a comparative single-center study found.

February 24, 2024

Stress of neighborhood poverty and community violence affects Black adolescents’ mental health

It’s easy to imagine that growing up in a neighborhood with safe and clean parks, little to no discrimination, and where people are not struggling

August 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.